Esperion shifts to show not tell
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
Asco-GU 2020: revving up for Peloton deal validation
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
Sanofi's geriatric pipeline fails to freshen up
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
The sellside falls out of love with Opdivo
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Blueprint beats Deciphera to the punch
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
Go or no go? Vascepa’s finale and Allergan's pain relief
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Novartis bets $9.7bn on RNA interference
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
